Literature DB >> 22873579

Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier.

Hidetoshi Arima1, Ayumi Yoshimatsu, Haruna Ikeda, Ayumu Ohyama, Keiichi Motoyama, Taishi Higashi, Akira Tsuchiya, Takuro Niidome, Yoshiki Katayama, Kenjiro Hattori, Tomoko Takeuchi.   

Abstract

We previously reported that of the various polyamidoamine (PAMAM) STARBURST dendrimer (generation 3, G3) (dendrimer) conjugates with cyclodextrins (CyDs), the dendrimer (G3) conjugate with α-CyD having an average degree of substitution of 2.4 (α-CDE (G3)) has the greatest potential for a novel carrier for siRNA in vitro and in vivo. To improve the siRNA transfer activity and the lack of target specificity of α-CDE (G3), we prepared folate-polyethylene glycol (PEG)-appended α-CDEs (G3) (Fol-PαCs) with various degrees of substitution of folate (DSF) and evaluated their siRNA transfer activity to folate receptor (FR)-overexpressing cancer cells in vitro and in vivo. Of the three Fol-PαCs (G3, DSF 2, 4 and 7), Fol-PαC (G3, DSF 4) had the highest siRNA transfer activity in KB cells (FR-positive). Fol-PαC (G3, DSF 4) was endocytosed into KB cells through FR. No cytotoxicity of the siRNA complex with Fol-PαC (G3, DSF 4) was observed in KB cells (FR-positive) or A549 cells (FR-negative) up to the charge ratio of 100/1 (carrier/siRNA). In addition, the siRNA complex with Fol-PαC (G3, DSF 4) showed neither interferon response nor inflammatory response. Importantly, the siRNA complex with Fol-PαC (G3, DSF 4) tended to show the in vivo RNAi effects after intratumoral injection and intravenous injection in tumor cells-bearing mice. The FITC-labeled siRNA and TRITC-labeled Fol-PαC (G3, DSF 4) were actually accumulated in tumor tissues after intravenous injection in the mice. In conclusion, the present results suggest that Fol-PαC (G3, DSF 4) could potentially be used as a FR-overexpressing cancer cell-selective siRNA delivery carrier in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22873579     DOI: 10.1021/mp300188f

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  20 in total

Review 1.  Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.

Authors:  Su-Tang Lo; Amit Kumar; Jer-Tsong Hsieh; Xiankai Sun
Journal:  Mol Pharm       Date:  2013-01-24       Impact factor: 4.939

Review 2.  MicroRNAs and DNA damage response: implications for cancer therapy.

Authors:  Yemin Wang; Toshi Taniguchi
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

3.  Polymer nanocarriers for MicroRNA delivery.

Authors:  Chintan H Kapadia; Benjamin Luo; Megan N Dang; N'Dea Irvin-Choy; Danielle M Valcourt; Emily S Day
Journal:  J Appl Polym Sci       Date:  2019-11-12       Impact factor: 3.125

Review 4.  Nanoparticle ligand presentation for targeting solid tumors.

Authors:  Jason T Duskey; Kevin G Rice
Journal:  AAPS PharmSciTech       Date:  2014-06-14       Impact factor: 3.246

Review 5.  High-density lipoproteins for the systemic delivery of short interfering RNA.

Authors:  Kaylin Marie McMahon; Colby Shad Thaxton
Journal:  Expert Opin Drug Deliv       Date:  2013-12-09       Impact factor: 6.648

6.  Revisiting the value of competition assays in folate receptor-mediated drug delivery.

Authors:  Steven K Jones; Anwesha Sarkar; Daniel P Feldmann; Peter Hoffmann; Olivia M Merkel
Journal:  Biomaterials       Date:  2017-05-22       Impact factor: 12.479

7.  Click hybridization of immune cells and polyamidoamine dendrimers.

Authors:  Leyuan Xu; Olga Yu Zolotarskaya; W Andrew Yeudall; Hu Yang
Journal:  Adv Healthc Mater       Date:  2014-02-13       Impact factor: 9.933

8.  Recent advances in targeted drug delivery approaches using dendritic polymers.

Authors:  Jason Bugno; Hao-jui Hsu; Seungpyo Hong
Journal:  Biomater Sci       Date:  2014-12-11       Impact factor: 6.843

9.  Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance.

Authors:  Steven K Jones; Vincent Lizzio; Olivia M Merkel
Journal:  Biomacromolecules       Date:  2015-12-16       Impact factor: 6.988

Review 10.  Twenty Years of Research on Cyclodextrin Conjugates with PAMAM Dendrimers.

Authors:  Hidetoshi Arima
Journal:  Pharmaceutics       Date:  2021-05-11       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.